118 related articles for article (PubMed ID: 2046387)
1. MY4 expression on B-lymphocyte malignancies may be associated with a more adverse prognosis.
Warzynski MJ; Otto RN; Steingart RH; White CF; Rosen MH; Hetzel PC; Flatow FA; Podgurski AE; Johnson ML
Leuk Res; 1991; 15(5):357-65. PubMed ID: 2046387
[TBL] [Abstract][Full Text] [Related]
2. [Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases].
Ling JY; Sun XF; Yan SL; He LR; Zhen ZJ; Xia Y
Ai Zheng; 2007 Apr; 26(4):418-22. PubMed ID: 17430665
[TBL] [Abstract][Full Text] [Related]
3. Myelomonocytic antigens are rarely expressed on B-lymphocytic leukemia cells.
Polliack A; Rabinowitz R; Leizerowitz R; Keren-Zur Y; Schlesinger M
Leuk Lymphoma; 1993 Jan; 9(1-2):125-31. PubMed ID: 8477192
[TBL] [Abstract][Full Text] [Related]
4. Human Lyb-2 homolog CD72 is a marker for progenitor B-cell leukemias.
Schwarting R; Castello R; Moldenhauer G; Pezzutto A; von Hoegen I; Ludwig WD; Parnes JR; Dörken B
Am J Hematol; 1992 Nov; 41(3):151-8. PubMed ID: 1384316
[TBL] [Abstract][Full Text] [Related]
5. Immunophenotypic evaluation of the bone marrow in non-Hodgkin's lymphoma.
Fineberg S; Marsh E; Alfonso F; Espiritu E; Gottesman SR; Amorosi E; Feiner HD
Hum Pathol; 1993 Jun; 24(6):636-42. PubMed ID: 8505041
[TBL] [Abstract][Full Text] [Related]
6. My4 antibody staining of non-Hodgkin's lymphomas.
Medeiros LJ; Herrington RD; Gonzalez CL; Jaffe ES; Cossman J
Am J Clin Pathol; 1991 Mar; 95(3):363-8. PubMed ID: 1705092
[TBL] [Abstract][Full Text] [Related]
7. Myelomonocytic antigens in B-cell chronic lymphocytic leukemia.
Tàssies D; Montserrat E; Reverter JC; Villamor N; Rovira M; Rozman C
Leuk Res; 1995 Nov; 19(11):841-8. PubMed ID: 8551801
[TBL] [Abstract][Full Text] [Related]
8. Variable expression of CD49d antigen in B cell chronic lymphocytic leukemia is related to disease stages.
Eksioğlu-Demiralp E; Alpdoğan O; Aktan M; Firatli T; Oztürk A; Budak T; Bayik M; Akoğlu T
Leukemia; 1996 Aug; 10(8):1331-9. PubMed ID: 8709639
[TBL] [Abstract][Full Text] [Related]
9. Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation.
Sánchez ML; Almeida J; Vidriales B; López-Berges MC; García-Marcos MA; Moro MJ; Corrales A; Calmuntia MJ; San Miguel JF; Orfao A
Leukemia; 2002 Aug; 16(8):1460-9. PubMed ID: 12145686
[TBL] [Abstract][Full Text] [Related]
10. Quantification of CD24 and CD45 antigens in parallel allows a precise determination of B-cell maturation stages: relevance for the study of B-cell neoplasias.
Lavabre-Bertrand T; Duperray C; Brunet C; Poncelet P; Exbrayat C; Bourquard P; Lavabre-Bertrand C; Brochier J; Navarro M; Janossy G
Leukemia; 1994 Mar; 8(3):402-8. PubMed ID: 8127145
[TBL] [Abstract][Full Text] [Related]
11. Expression of the activation antigen, 4F2, by non-Hodgkin's lymphomas of B-cell phenotype.
Lewandrowski KB; Medeiros LJ; Harris NL
Cancer; 1990 Sep; 66(6):1158-64. PubMed ID: 1698116
[TBL] [Abstract][Full Text] [Related]
12. Three new monoclonal antibodies that define a unique antigen associated with prolymphocytic leukemia/non-Hodgkin's lymphoma and are effectively internalized after binding to the cell surface antigen.
Okazaki M; Luo Y; Han T; Yoshida M; Seon BK
Blood; 1993 Jan; 81(1):84-94. PubMed ID: 8417805
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of residual disease in B-cell chronic lymphocytic leukemia patients in clinical and bone-marrow remission using CD5-CD19 markers and PCR study of gene rearrangements.
Vuillier F; Claisse JF; Vandenvelde C; Travade P; Magnac C; Chevret S; Desablens B; Binet JL; Dighiero G
Leuk Lymphoma; 1992 Jun; 7(3):195-204. PubMed ID: 1282428
[TBL] [Abstract][Full Text] [Related]
14. Phenotypic heterogeneity of B cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Kampalath B; Barcos MP; Stewart C
Am J Clin Pathol; 2003 Jun; 119(6):824-32. PubMed ID: 12817430
[TBL] [Abstract][Full Text] [Related]
15. FMC7 antigen expression on normal and malignant B-cells can be predicted by expression of CD20.
Hübl W; Iturraspe J; Braylan RC
Cytometry; 1998 Apr; 34(2):71-4. PubMed ID: 9579603
[TBL] [Abstract][Full Text] [Related]
16. Association of bone marrow growth pattern, coexpression of CD14, and B-cell CD5 antigen density in 45 B-chronic lymphocytic leukemia (B-CLL) patients.
Paglieroni T; Caggiano V; MacKenzie MR
Ann N Y Acad Sci; 1992 May; 651():484-5. PubMed ID: 1376066
[No Abstract] [Full Text] [Related]
17. The monoclonal antimonocyte antibody My4 stains B lymphocytes and two distinct monocyte subsets in human peripheral blood.
Ziegler-Heitbrock HW; Passlick B; Flieger D
Hybridoma; 1988 Dec; 7(6):521-7. PubMed ID: 2466760
[TBL] [Abstract][Full Text] [Related]
18. CD30 distribution. Immunohistochemical study on formaldehyde-fixed, paraffin-embedded Hodgkin's and non-Hodgkin's lymphomas.
Miettinen M
Arch Pathol Lab Med; 1992 Nov; 116(11):1197-201. PubMed ID: 1332642
[TBL] [Abstract][Full Text] [Related]
19. Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia.
Almasri NM; Duque RE; Iturraspe J; Everett E; Braylan RC
Am J Hematol; 1992 Aug; 40(4):259-63. PubMed ID: 1380203
[TBL] [Abstract][Full Text] [Related]
20. De novo CD5-positive and Richter's syndrome-associated diffuse large B cell lymphomas are genotypically distinct.
Matolcsy A; Chadburn A; Knowles DM
Am J Pathol; 1995 Jul; 147(1):207-16. PubMed ID: 7541611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
